. The observed duration of effectiveness varied from 8 months to more than 24 months and it seems that it is not only dose dependent. Authors agree that the implant should be inserted until the age of 4-5 months at latest since later application can induce puberty (Kaya et al., 2013; Palm & Reichler, 2012; Trigg et al., 2006) . The effects of the GnRH agonists on body development have been studied by different groups who in part used different protocols. Most authors describe normal body development when one implant was used. However, juvenile appearance of the vulva at the end of the observation period was evident, when three 4.7 mg implants were inserted, one at the age of 4.5, 8 and 13.5 months each (Marino et al., 2014) . In an own study, we investigated the effect of one 4.7 or 9.4 mg deslorelin implant on epiphyseal closure; we observed occurrence of epiphyseal closure at the time of puberty or shortly before, namely after 83.5 weeks with the 9.4 mg implant, after 73.4 weeks with 4.7 mg and after 60.9 weeks in the non-treated controls (p < 0.05; Kaya et al., 2015) . In contrary, the vulva was normally developed. We therefore concluded, that local effects are not only age related but also dependent on dosage and constancy of serum concentrations. With more than one implant the suppression obviously was more continuous and body development was similar to juvenile castration (Marino et al., 2014) .
We therefore started to investigate the local effects on reproductive organs; first on canine luteal function following the first oestrus. When one implant was given at the age of 4 months, no negative effect was seen on the ovaries of bitches, neither macroscopically nor histologically, and ovarian functionality was not impaired . We thereafter were interested to elucidate the effect of long-term pre-pubertal GnRH agonist treatment on uterine tissues which was the aim of this study.
| MATERIAL SANDME THODS

| Animals
Uterine tissue samples from the same animals as in a previous study (Kaya et al., 2015) were used. Briefly, eleven cross-breed, pre-pubertal bitches aged 4.2 ± 0.6 m, body weight range: 6-15 kg [Group 1 (9.4 mg): 8.56 kg; Group 2 (4.7 mg): 8.95 kg; Group 3 (control): 9.85 kg], were used. The bitches were diagnosed to be prepubertal after gynecological examination, vaginal cytology, and serum estradiol 17β (E 2 ) and progesterone (P 4 ) measurement.
All experimental procedures were reviewed and approved by the Local Animal Ethics Committee of the Faculty of Veterinary Medicine, Kafkas University, Turkey (KAÜ-HADYEK; 2014/016).
| Implantinsertion,monitoringandsampling
Implants containing placebo (sodium chloride 0.9%; n = 4, G I), 4.7 mg (n = 3, GII) or 9.4 mg (n = 4, GIII) deslorelin (Suprelorin; Virbac, France), were administered subcutaneously (s.c) in the inter-scapular region. Signs of oestrus (vulvar swelling, vaginal fluor and sexual attractiveness) and sexual behavioural changes were monitored once daily, until the occurrence of oestrus. A swab for vaginal cytology was taken every other day, and in addition blood for measurement of serum P4 and E2 concentrations. Two bitches in GII and GIII each came into oestrus after 82.7 ± 8.9 weeks after implantation and the controls after 61.9 ± 9.7 weeks. These animals were subjected to ovariohysterectomy (OHE) 30-45 days later, and uterine samples were collected.
Some treated bitches (n = 1 in G II and n = 2 in G III) did not show oestrus by the end of the observation period (up to 101 weeks) and were operated. In addition to comparison between groups I-III, experimental animals that came into heat were compared with controls and those that did not enter oestrus within the observation periodirrespective of the implant they received.
| Ovariohysterectomy
Ovariohysterectomy was performed under general anaesthesia, after written consent of the owner was obtained. Pre-anaesthetic medication consisted of atropine sulphate (Atropin, 2 mg/ml concentration; Vetaş 
| Hormonemeasurements
Blood samples were centrifuged for 3 min at 3,000 g and the sera stored at −18°C until analyses. The concentrations of P4 (ng/ml) and E2 (pg/ml) were measured using the Electrochemiluminescence Immunoassay (ECLIA) with a fully automated Cobas Modular E170
Analyzer (Roche Diagnostics, Mannheim, Germany) in an internationally certified commercial laboratory (Düzen Laboratories Group, Ankara, Turkey) as described by Agaoglu et al. (2011) . Extraction efficiency was >95%. The mean intra-and inter-assay coefficients of variance for P4 were 3.2% and 1.7%, respectively. The analytic sensitivity was 0.03 ng/ml. Values for E2 assay were 5.0 pg/ml (sensitivity), 3.0% (intra-assay coefficient) and 1.7% (inter-assay coefficient).
| Morphometricmeasurements
For the morphologic analysis of the uterine tissues, uterine tissue diameters, thickness of uterine endometrium and myometrium were measured by using the Nikon Eclipse E600 microscope (Nikon | 105
Instruments, Inc., Melville, New York, USA). Measurements were evaluated by using the firmware "DS-L1 Ver3.22" which is provided together with the microscope.
Uterine gland maturity was assessed microscopically by evaluating uterine gland cell nuclear-cytoplasmic ratio, nuclear basophilia, the shape of the nucleus, structure and outline of the cell membrane, and location of the nucleus within the cell.
| Immunohistochemistry
Sections ( 
| ImmunoreactivityScore(IRS)
Tissue sections were scored semi-quantitatively for immunolabelling.
All uterine tissue sections were scanned for the positively labelled cells. The extent of reactivity was evaluated semi-quantitatively by the ratio (%) of positively stained cell types and total number of the same cell types at x200 final magnification. A total area of on average 0.05 mm 2 was examined. Labelling intensity was quantified using a four-point score scale: 0 = no labelling; 1 = weak labelling; 2 = moderate labelling; 3 = intense immunolabelling. An immunoreactivity score (IRS) was obtained by multiplying the immunolabelling intensity score (0-3) with the percentage of immunlolabelled cell types being investigated. The IRS ranged from 0 to a maximum value of 300 (Sözmen & Beytut, 2012; Sözmen, Tunca, & Erginsoy, 2009 ).
| Statisticalanalyses
All statistical analyses were performed using IBM SPSS statistics version 24 (SPSS Ltd; Hong Kong). Data are given as means ± standard error (SEM). The normality and homogeneity of variances were checked for all variables tested by means of a "Shapiro-Wilks" test and "Bartlett-Box" test. For normally distributed data, differences between groups were compared using "t test". For non-normality data, the "Mann-Whitney-U" test was used. The "Friedman Test"
was performed due to the small number of data and non-normal distribution. After the "Friedman Test," results were statistically tested for significant differences between two groups using the "Wilcoxontest." Values of p < 0.05 were considered statistically significant.
| RE SULTS
| Clinicalfindings
No clinically detectable local or systemic side effects were observed in any of the treated animals. Furthermore, after ovariohysterectomy, tissue samples were examined macroscopically and no abnor- 
| Serumprogesteronandoestrogen concentrations
The mean P4 concentrations in control and deslorelin-treated bitches were 53.79 ± 6.21 ng/ml and 48.93 ± 6.97 ng/ml at the time of tissue collection, respectively (p > 0.05). The mean E2 concentrations ranged from 6 to 42 pg/ml in control (28.5 ± 7.79 pg/ml) and 6-90 pg/ml (38.73 ± 19.99 ng/ml) in deslorelin-treated bitches (p > 0.05).
| Morphometricanalyses
Morphometrical tissue analysis after OHE revealed no significant difference between the 4.7 mg suprelorin group and the controls, concerning the endometrial and myometrial thickness, and the diameter of the uterus, respectively. However, in the 9.7 mg suprelorin group, the average uterine diameter was significantly lower in comparison to the controls (4071.4 ± 825.5 μm vs 6729.2 ± 905.7 μm, p < 0.05); and the average endometrial thickness of the 9.4 mg suprelorin group was significantly lower than in the 4.7 mg group (888.1 ± 249.6 μm vs 1302.6 ± 137.8 μm, p < 0.05). Furthermore, within the group of 9.4 mg animals, the prepubertally castrated showed a significant thinner myometrium than those castrated in metestrus (312.4 ± 24.7 μm vs 1371.7 ± 343.7 μm). There was no significant difference between groups in terms of adenogenesis, all groups and tissues showed the same maturity of uterine glands.
| Immunohistochemistry
All results are summarized in Table 1 .
The KP 10 protein signals varied widely among the groups and individuals, irrespective of the implant and whether still pre-pubertal or not. Kisspeptin 10 protein staining was generally low in all the cell types evaluated. Highest IRS was observed in uterine tissues of the controls (Table 1) Similarly, GnRH-R staining was negative for all the groups and cells studied, while luteal cells from positive control tissue of the canine ovary revealed diffuse cytoplasmic staining (Figure 6 ).
TA B L E 1 Immunoreactivity scores (IRS)
a of uterine tissues of control and experimental groups, after pre-pubertal application of 4.7 or 9.4 mg of deslorelin 
| D ISCUSS I ON
Recently, we could show that pre-pubertal application of one 4.7 or 9.4 mg deslorelin implant was without a negative effect on later ovarian function of bitches . Even though the bitches in the different groups did not have the same body weight and belonged to different breeds, all were truly pre-pubertal as proven by clinical and cytological examination and hormonal measurement. This is important for any study concerning pre-pubertal bitches (Gobello, 2014) . All bitches came into oestrus and had P4 levels (31 ->60 ng/ml) indicating ovulations, even though luteinized follicles without ovulation cannot be excluded; the histological and micromolecular investigation of the ovaries revealed no abnormalities.
In this follow-up study, we aimed to investigate the effect of puberty postponement on the uterine tissue of the same bitches.
We observed no macroscopical or histological changings in comparison to the non-treated controls. This was expected since uterine development should be finalized at the age of 4 months; uterine adenogenesis was reported to be completed at the age of 6-8 weeks (Cooke et al., 2012) . Furthermore none of the bitches showed any uterine disease which is important for their later breeding fitness; so far, no clinical abnormalities were seen after delay of puberty with GnRH agonists (Fontaine et al., 2012; Kaya et al., 2013 Kaya et al., , 2015 et al. (2014) reported that after delay of puberty and consecutive castration at the age of 18 months, the uterine horns were thin and long and the cervix narrow; histologically, the uterus showed a thin myometrial layer and an endometrium with scattered immature endometrial glands. In this study, the bitches were castrated while still suppressed, the suppressive effect of the three implants, applicated in rather short intervals, on the endometrium was very strong. Unfortunately, Marino et al. (2014) did not investigate the local receptor expression; the bitches were monitored clinically, ultrasonographically and endocrinologically. In our study, the results were similar, except that the glands occurred mature, which according to Cooke et al. (2012) should be normal at this age in intact bitches. With one implant as applicated in our study, the ripening of the glands obviously was not disturbed, just delayed.
After occurrence of puberty and consecutive castration, the uterine diameter and endometrial thickness was significantly lower in the 9.4 mg group than in the controls, but not in the 4.7 mg group. This might indicate a prolonged suppressive effect of the 9.4 mg implant on uterine development. It will be interesting to investigate after which time after occurrence of puberty the uterine development is complete in the 9.4 mg group.
However, the uterine receptor expression after puberty delay was not investigated before. The main differences concerned the cycle stages since some animals came into oestrus and were operated in metestrus, like the controls, others were ovariohysterectomized while still pre-pubertal. The immunohistological results revealed that the impact of the deslorelin dosage was low, whereas in case of the GPR54 and the ERα,β it made a difference whether the bitches were still pre-pubertal or not when castrated. The GPR54 was positively labelled mainly in superficial and deep uterine gland cells of dogs that were still pre-pubertal;
in those castrated in their first metestrus, the results were similar to the controls. The KP 10 labelling revealed no differences between groups, only individual differences are worth mentioning.
Nevertheless, we believe that the high numbers of ERα,β expressing cells in pre-pubertal animals are related to the physiological changings during puberty, and not dependent on delay of puberty with deslorelin; the slow increase in secretory kisspeptin and GnRH pulses from the hypothalamus shortly before puberty is accompanied by an increasing sensitivity of the receptors. And it is well known that puberty is preceded by an upregulation of oestrogen receptors in the central nervous system and other organs that in addition become more and more sensitized for oestrogen (Concannon, 1993) . The same has been observed in the ovaries.
Even though in most cases no oestrogen is measurable at the age of 4-5 months, increased DHEA concentrations were measured in pre-pubertal bitches (Lacoste, Dubé, Trudel, Bélanger, & Labrie, 1989) ; and folliculogenesis starts as early as 2-12 weeks postnatally (Blackmore et al., 2004 The expression of kisspeptin receptor in the pre-pubertal uterus of bitches has not been described before; only one study reports about the expression of kisspeptin and its receptor in the canine pregnant uterus and trophoblast cells .
However, since no control bitch was castrated before puberty, we cannot directly compare the results of those experimental bitches that did not enter oestrus during the observation period. The question remains, whether the here observed comparably high immunolabelling of the GPR54 is related to delay of puberty with deslorelin or just related to the physiological changings preceding puberty.
| CON CLUS IONS
We conclude that ovarian functionality, serum steroid hormone concentrations and uterine health were normal after delay of puberty with 4.7 or 9.4 mg of deslorelin, all bitches had ovulations and cycled normally (Kaya et al., 2015 . However, follow-up studies shall reveal the fertility of these bitches. In adult bitches, repeated insertion of a deslorelin implant did not impair fertility in one study (Borges et al., 2015) ; this was not investigated after delay of puberty yet.
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